Site is Being Upgraded

Diabetic retinopathy

August 19, 2018

Repurposing the anti-angina drug Ranolazine into a diabetes retinopathy drug: A pharmaceutical mixture encompassing Ranolaxine, Epicatechin and Matrine (REM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down-regulation of its target gene, 20/August/2018, 12.05 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
June 29, 2018

Bacillus Calmette Guerin (BCG) vaccine-based therapy for Diabetic retinopathy: BCG vaccine inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/June/2018, 11.15 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
June 23, 2018

Unearthing an unknown function of a known drug: Natural product-based combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Telmisartan(angiotensin II receptor antagonist), Epicatechin and Matrine (TEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 23/June/2018, 7.33 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
June 9, 2018

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-Galactosylceramide, Epicatechin and Matrine (GCEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 9/June/2018, 10.49 pm

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]